Understanding the cellular mechanism of HDAC inhibitors for the treatment of NPC disease

Deepti Gadi, Ph.D.
NNPDF Peter D. Pentchev Research Fellow
Principal Investigator: Dr. Frederick R. Maxfield

Lay Summary for Progress Report #1 (October 2012 – March 2013)

Niemann Pick type C disease is caused due to mutations in NPC1 or NPC2 protein resulting in an accumulation of cholesterol in the cells. We previously demonstrated that histone deacetylase inhibitors (SAHA and LBH589) can reduce cholesterol level in NPC patient fibroblast (skin) cells and increase NPC1 protein level. SAHA (also called Vorinostat), is an FDA-approved drug for treatment of a cancer, and we are seeking approval from the FDA for tests in NPC patients. Merck, the patent holder, has agreed to assist Lysomics LLC, a company formed to develop histone deacetylase inhibitors for the treatment of lysosomal disorders, in the application to the FDA and to provide the drug for approved clinical trials.

The fellowship proposal is to study the mechanism by which histone deacetylase inhibitors are reducing cholesterol levels in patient fibroblast cells. Determining how histone deacetylase inhibitors are correcting the NPC phenotype would lay the basis for targeted therapy based on genetic screening of NPC patients expressing unique mutations. We proposed that the mechanism by which SAHA is correcting cholesterol levels is by enhancing the expression of protein chaperones in the cells, which results in an increase in NPC1 protein. We checked for expression level of different chaperones in SAHA-treated cells and found an increase in BiP, a chaperone that may assist in getting NPC1 protein to the correct cellular organelles. We plan to test if BiP is involved in SAHA-mediated reduction of cholesterol by reducing the expression of BiP in cells.

Also, we are investigating whether more selective histone deacetylase inhibitors will also reduce cholesterol storage. This might lead to a more selective drug than SAHA for the treatment of NPC disease with reduced off-target effects.